Navigation Links
OncoSec Medical Announces $7.2 Million Public Offering
Date:12/13/2012

SEC's website at www.sec.gov or by request at Dawson James Securities, Inc. by e-mailing placements@djsiny.com.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of OncoSec's common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's cu
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... Antonio, TX (PRWEB) July 22, 2014 Dr. ... Designed with existing patients and new visitors in mind, one ... clean, modern and visual layout that makes navigation very easy. ... make the experience of going to the dentist affordable, convenient ... , One helpful new feature is an appointment scheduling system ...
(Date:7/22/2014)... Indianapolis, IN (PRWEB) July 22, 2014 ... benefits advisory organization, announces that Les McPhearson, an insurance ... serve as CEO effective immediately and be based in ... Calise, said, "I am delighted that Les chose to ... is perfectly qualified to address the many challenges facing ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 (HealthDay ... in the veins of the legs appear no different in ... risk of bleeding and average hospitalization bills that are three ... finds. The standard treatment for these clots -- known ... compression stockings. The other, more expensive treatment delivers medication directly ...
(Date:7/22/2014)... 22, 2014) The American Society of Hematology (ASH) ... School of Medicine, and Robert P. Hebbel, MD, of ... Ernest Beutler Lecture and Prize for their significant research ... The Ernest Beutler Lecture, named for the late Ernest ... for more than 50 years, is a two-part lectureship ...
(Date:7/22/2014)... research at the University of Utah,s John A. Moran ... of Eye Research (ISER) as the recipient of the ... Award in Retina Research., The award recognizes lifetime achievement ... contribution to the understanding of vitreoretinal diseases or disorders. ... ISER Biennial Meeting in San Francisco, where Marc will ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Rostock Center for the study of Demographic Change, have ... be //soon reduced, if the trend of low participation ... ,The Rostock Center is a research institution, ... for Demographic Research and the University of Rostock. The ...
... lead in a global ,program to catalogue human mutations in ... access//. ,For a sample of the expected ... professor at the division of human genetics at the University ... a family who suffered from a heredity eye disease, which ...
... A Geography professor of Kansas State University, Doug Goodin, ... of land use and land cover //changes on human ... uses, combines remote sensing with other types of data, ... Along with other scientists he recently discussed this subject ...
... Chicago – The extended use of anabolic androgenic steroid ... // Gingival enlargement occurs when the tissues ... is a fertile environment for bacteria to grow, which ... that AAS abusers had statistically significant levels of gingival ...
... of misconception about Cannabis and its effects. It is widely ... // Such misrepresentations of the drug have resulted in making ... Karolinska Institute in Sweden have unearthed the harmful effects of ... ingredient in cannabis. It was found that the brain of ...
... medical specialist, NHS can be freed from its’ problems, ... before they are implemented. // It is amply clear ... make matters worse for the deprived and under privileged ... led to low morale among Doctors and NHS staff. ...
Cached Medicine News:Health News:Demographic Change Demand a New Life-Course for Aging Society 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 3Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:A connection between gingival enlargement and steroid abuse 2
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: